John P Overington
Overview
Explore the profile of John P Overington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
9030
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Moya-Garcia A, Adeyelu T, Kruger F, Dawson N, Lees J, Overington J, et al.
Sci Rep
. 2017 Sep;
7(1):10102.
PMID: 28860623
Protein domains mediate drug-protein interactions and this principle can guide the design of multi-target drugs i.e. polypharmacology. In this study, we associate multi-target drugs with CATH functional families through the...
12.
Zwierzyna M, Overington J
PLoS Comput Biol
. 2017 Jul;
13(7):e1005641.
PMID: 28678787
Testing potential drug treatments in animal disease models is a decisive step of all preclinical drug discovery programs. Yet, despite the importance of such experiments for translational medicine, there have...
13.
Schmidt A, Pearce L, Wilkins J, Overington J, Hingorani A, Casas J
Cochrane Database Syst Rev
. 2017 Apr;
4:CD011748.
PMID: 28453187
Background: Despite the availability of effective drug therapies that reduce low-density lipoprotein (LDL)-cholesterol (LDL-C), cardiovascular disease (CVD) remains an important cause of mortality and morbidity. Therefore, additional LDL-C reduction may...
14.
Martinez-Jimenez F, Overington J, Al-Lazikani B, Marti-Renom M
Sci Rep
. 2017 Apr;
7:46632.
PMID: 28436422
Drug resistance is one of the major problems in targeted cancer therapy. A major cause of resistance is changes in the amino acids that form the drug-target binding site. Despite...
15.
Finan C, Gaulton A, Kruger F, Lumbers R, Shah T, Engmann J, et al.
Sci Transl Med
. 2017 Mar;
9(383).
PMID: 28356508
Target identification (determining the correct drug targets for a disease) and target validation (demonstrating an effect of target perturbation on disease biomarkers and disease end points) are important steps in...
16.
Santos R, Ursu O, Gaulton A, Bento A, Donadi R, Bologa C, et al.
Nat Rev Drug Discov
. 2016 Dec;
16(1):19-34.
PMID: 27910877
The success of mechanism-based drug discovery depends on the definition of the drug target. This definition becomes even more important as we try to link drug response to genetic variation,...
17.
Gaulton A, Hersey A, Nowotka M, Bento A, Chambers J, Mendez D, et al.
Nucleic Acids Res
. 2016 Dec;
45(D1):D945-D954.
PMID: 27899562
ChEMBL is an open large-scale bioactivity database (https://www.ebi.ac.uk/chembl), previously described in the 2012 and 2014 Nucleic Acids Research Database Issues. Since then, alongside the continued extraction of data from the...
18.
Williamson A, Ylioja P, Robertson M, Antonova-Koch Y, Avery V, Baell J, et al.
ACS Cent Sci
. 2016 Nov;
2(10):687-701.
PMID: 27800551
The development of new antimalarial compounds remains a pivotal part of the strategy for malaria elimination. Recent large-scale phenotypic screens have provided a wealth of potential starting points for hit-to-lead...
19.
Mutowo P, Bento A, Dedman N, Gaulton A, Hersey A, Lomax J, et al.
J Biomed Semantics
. 2016 Sep;
7(1):59.
PMID: 27678076
Background: The process of discovering new drugs is a lengthy, time-consuming and expensive process. Modern day drug discovery relies heavily on the rapid identification of novel 'targets', usually proteins that...
20.
Christmann-Franck S, van Westen G, Papadatos G, Beltran Escudie F, Roberts A, Overington J, et al.
J Chem Inf Model
. 2016 Aug;
56(9):1654-75.
PMID: 27482722
Drug discovery programs frequently target members of the human kinome and try to identify small molecule protein kinase inhibitors, primarily for cancer treatment, additional indications being increasingly investigated. One of...